glp 1 agonist tirzepatide Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Response in Type 2 Diabetes and Atherosclerosis Beyond GLP-1: New 5-In-1 Compound

10.1016/j.nlm.2019.04.009 Neurobiol

LIPO-C is generally well-tolerated when administered correctly, but localised injection site reactions (redness, swelling, tenderness) occur in 1020% of patients during the first few weeks

The 0.2mg and 0.1mg doses achieved 36% and 40% NASH resolution, respectively

doi:10.1002/cber.18780110151

In fact, research indicates that people using semaglutide lose an average of up to 6% of their total body weight in three months and up to 11% in six months

Your provider will review your full health history, order relevant labs, and build a protocol around your specific biology and goals guiding you from your first injection through long-term maintenance